Stop the denosumab delay! The effect of implementing an automatic reminder in the electronic medical record

Arch Osteoporos. 2022 Jan 20;17(1):18. doi: 10.1007/s11657-022-01065-1.

Abstract

Delays in denosumab dosing for osteoporosis treatment may lead to rapid bone loss or increased fractures. We assessed the frequency of delayed denosumab dosing before and after the implementation of a structured ordering plan with automated reminders and found that the rate of delayed denosumab dosing was cut in half.

Purpose: The purpose of our study was to assess the frequency of delayed denosumab dosing before and after the implementation of a structured ordering plan with automated reminders.

Methods: We conducted a retrospective chart review of 720 adults with osteoporosis who received at least two denosumab doses within the UCHealth system before and after the plan went into effect.

Results: There was a significant reduction in delayed dosing from 24.0% (PRE) to 12.6% (POST) (p < 0.001) after implementation of the automated reminder. The fraction of delayed denosumab doses due to scheduling issues decreased significantly between PRE and POST time periods (16.4% vs. 3.3%, p = 0.011), while patient-related issues increased from 31.2% to 46.7% (p = 0.041). The rate of provider, medical, and other/unknown issues did not differ between the two time periods. When normalized to patient-years of follow-up, the number of fractures was the same for both groups at 0.016 fractures per patient-year. Fractures in both the PRE and POST groups were related to dosing delays, but the study was not powered to detect the differences in fracture rates between the groups.

Conclusion: Electronic records with automatic reminders can reduce delayed dosing of denosumab and may lead to reductions in fractures associated with delays.

Keywords: Automated renewal reminders; Denosumab; Medication adherence; Osteoporosis; Quality improvement.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Bone Density
  • Bone Density Conservation Agents*
  • Denosumab / therapeutic use
  • Electronic Health Records
  • Female
  • Humans
  • Osteoporosis* / drug therapy
  • Osteoporosis, Postmenopausal* / drug therapy
  • Retrospective Studies

Substances

  • Bone Density Conservation Agents
  • Denosumab